Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “AstraZeneca”

eVusheld Assessment reaL wORld Effectiveness at UPMCCompleted
NCT05667116N/AUpdated Nov 12, 2024
Sponsor: AstraZeneca
SARS-CoV-2, COVID-19
United States
Study to Access Safety of Durvalumab in Indian Adult Patients With Locally Advanced NSCLCCompleted
NCT04416633Phase 4Updated Nov 8, 2024
Sponsor: AstraZeneca
Unresectable Non-small Cell Lung Cancer (NSCLC)
India
An Observational Study of Patients Receiving T-DXd for Treatment of HER2+, and HER2-low Unresectable and/or Metastatic Breast CancerTerminated
NCT05592483N/AUpdated Nov 7, 2024
Sponsor: AstraZeneca
Breast Cancer
United States, Austria, Brazil, Canada, Israel +4 more
Phase II AZD9291 Open Label Study in NSCLC After Previous EGFR TKI Therapy in EGFR and T790M Mutation Positive TumoursCompleted
NCT02094261Phase 2Updated Nov 6, 2024
Sponsor: AstraZeneca
Non Small Cell Lung Cancer
United States, Canada, Hong Kong, Italy, Japan +3 more
Assess the Safety of Immunotherapy Induction With Tremelimumab and Durvalumab Prior to Chemoradiotherapy and/or Resection in the TreatmentTerminated
NCT04287894Phase 1Updated Nov 6, 2024
Sponsor: The Netherlands Cancer Institute
Stage III NSCLC
Netherlands
First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid TumoursCompleted
NCT04504669Phase 1Updated Nov 5, 2024
Sponsor: AstraZeneca
Clear Cell Renal Cell Cancer · Non-Small-Cell Lung Cancer · Triple Negative Breast Neoplasms · Squamous Cell Cancer of Head and Neck
United States, Canada, France, Spain
Neoadjuvant Durvalumab and Tremelimumab Plus Radiation for High Risk Soft-Tissue SarcomaTerminated
NCT03116529Phase 1, Phase 2Updated Nov 4, 2024
Sponsor: University of Maryland, Baltimore
Soft Tissue Sarcoma
United States
MEDI4736 Combinations in Metastatic Renal Cell CarcinomaCompleted
NCT02819596Phase 2Updated Nov 4, 2024
Sponsor: Queen Mary University of London
Renal Clear Cell Carcinoma · Renal Papillary Cell Carcinoma
United Kingdom
Study of Osimertinib + SRS vs Osimertinib Alone for Brain Metastases in EGFR Positive Patients With NSCLCActive Not Recruiting
NCT03769103Phase 2Updated Oct 31, 2024
Sponsor: British Columbia Cancer Agency
Lung Cancer Non-small Cell Stage IV · Brain Metastases
Canada
NAsal Polyps: Inflammatory & Molecular Phenotyping of Responders to BenralizumabCompleted
NCT04185012Phase 3Updated Oct 31, 2024
Sponsor: Humanitas Clinical and Research Center
Nasal Polyps
Italy
Technology-Assisted Cholesterol Trial in Consumers (TACTiC)Completed
NCT04964544Phase 3Updated Oct 30, 2024
Sponsor: AstraZeneca
High Cholesterol
United States
Efficacy and Safety of Olaparib (MK-7339) With or Without Bevacizumab Compared to Bevacizumab With a Fluoropyrimidine in Unresectable or Metastatic Colorectal Cancer (CRC) (MK-7339-003/LYNK-003)Completed
NCT04456699Phase 3Updated Oct 29, 2024
Sponsor: Merck Sharp & Dohme LLC
Metastatic Colorectal Cancer
United States, Australia, Belgium, Canada, Chile +13 more
A Study of Tumor-Treating Fields in Combination With Durvalumab and Gemcitabine/Cisplatin in Biliary Tract CancersRecruiting
NCT06611345NAUpdated Oct 26, 2024
Sponsor: Jiangsu Healthy Life Innovation Medical Technology Co., Ltd
Biliary Tract Cancers (BTC)
China
A Study of Andexanet Alfa in Patients Requiring Urgent Surgery or ProcedureWithdrawn
NCT05926349Phase 3Updated Oct 26, 2024
Sponsor: AstraZeneca
Urgent Surgery
NEoadjuvant Olaparib Combination OvArian Cancer Targeted StudyNot Yet Recruiting
NCT06650709Phase 2Updated Oct 23, 2024
Sponsor: British Columbia Cancer Agency
Ovarian Cancer Stage IV
A Randomized, Open-label, Dose-ranging Study in Adults and Pediatric Individuals ≥ 12 Years of Age to Assess the Safety, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of AZD7442, for Pre-exposure Prophylaxis of COVID-19Terminated
NCT05375760Phase 2Updated Oct 23, 2024
Sponsor: AstraZeneca
Coronavirus Disease 2019 (COVID-19)
United States
Monalizumab and Trastuzumab In Metastatic HER2-pOSitive breAst Cancer: MIMOSA-trialCompleted
NCT04307329Phase 2Updated Oct 22, 2024
Sponsor: The Netherlands Cancer Institute
Breast Cancer
Netherlands
Osimertinib Then Chemotherapy in EGFR-mutated Lung Cancer with Osimertinib Third-line RechallengeRecruiting
NCT04335292Phase 2Updated Oct 22, 2024
Sponsor: Mark Vincent
Non-Small Cell Lung Cancer
Canada
A Molecular Profiling Study of Patients With EGFR Mutation-positive Locally Advanced or Metastatic NSCLC Treated With OsimertinibCompleted
NCT03239340Phase 2Updated Oct 21, 2024
Sponsor: AstraZeneca
EGFR Mutation Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer
United States, Italy, Malaysia, South Korea, Spain
Real World Evidence of Benralizumab in Eosinophilic Severe AsThma in Russia (BEST)Completed
NCT05271526N/AUpdated Oct 21, 2024
Sponsor: AstraZeneca
Severe Eosinophilic Asthma
Russia
Olaparib and Durvalumab (MEDI4736) in Patients with Metastatic Pancreatic Cancer and DNA Damage Repair Genes AlterationsActive Not Recruiting
NCT05659914Phase 2Updated Oct 18, 2024
Sponsor: Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Metastatic Pancreatic Cancer
Spain
Analysis of Olaparib Response in Patients With BRCA1 and/or 2 Promoter Methylation Diagnosed of Advanced Breast CancerCompleted
NCT03205761Phase 2Updated Oct 18, 2024
Sponsor: Spanish Breast Cancer Research Group
Advanced Breast Cancer
Spain
AZD7442 - a Potential Combination Therapy for the Prevention and Treatment of COVID-19Completed
NCT04507256Phase 1Updated Oct 18, 2024
Sponsor: AstraZeneca
COVID-19
United Kingdom
A Study to Investigate the Relative Bioavailability of AZD8630 Following a Device and Formulation Transition in Healthy Participants.Completed
NCT06531811Phase 1Updated Oct 17, 2024
Sponsor: AstraZeneca
Healthy Participants
United States
Cardiotoxicities in Patients Receiving BTKiWithdrawn
NCT05521178N/AUpdated Oct 15, 2024
Sponsor: Dana-Farber Cancer Institute
Chronic Lymphocytic Leukemia · Small Lymphocytic Lymphoma

Previous page Next page